Fig. 1From: Predictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancerWaterfall plots of relative PSA decline from baseline for patients with (a) and without (b) clinical progression during study follow-up (median 15 months). A decline of ≥90% was seen in 23 (65.7%) and 37 (84.1%) patients in (a) and (b) respectively. This was not statistically significant (p = 0.06). The bold reference line represents PSA decline of 90%Back to article page